H.C. Wainwright initiated coverage of Sensei Biotherapeutics with a Buy rating and $4 price target. Sensei is a clinical-stage biopharmaceutical company focusing on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases, the analyst tells investors in a research note. The firm says the company’s Anti-VISTA program has encouraging preclinical and Phase 1 clinical data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNSE:
- Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Sensei Biotherapeutics reports Q3 EPS (28c) vs (44c) last year
- Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- Sensei Biotherapeutics reports ‘favorable’ clinical data for SNS-101
- Sensei Biotherapeutics appoints Krebs as Chief Business Officer
